Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$192K Buy
6,843
+319
+5% +$8.49K 0.04% 110
2025
Q4
$162K Sell
6,524
-762
-10% -$19.2K 0.03% 117
2025
Q3
$186K Sell
7,286
-195
-3% -$4.81K 0.04% 110
2025
Q2
$181K Sell
7,481
-1,165
-13% -$27.2K 0.04% 111
2025
Q1
$219K Buy
8,646
+61
+0.7% +$1.6K 0.05% 95
2024
Q4
$228K Sell
8,585
-23
-0.3% -$624 0.06% 92
2024
Q3
$249K Buy
8,608
+8
+0.1% +$233 0.07% 90
2024
Q2
$241K Buy
8,600
+199
+2% +$5.48K 0.07% 88
2024
Q1
$233K Sell
8,401
-144
-2% -$4K 0.08% 87
2023
Q4
$246K Sell
8,545
-3,209
-27% -$97K 0.09% 84
2023
Q3
$390K Buy
11,754
+39
+0.3% +$1.38K 0.16% 71
2023
Q2
$430K Sell
11,715
-318
-3% -$12.4K 0.18% 69
2023
Q1
$491K Sell
12,033
-8
-0.1% -$346 0.2% 64
2022
Q4
$617K Buy
12,041
+105
+0.9% +$5.03K 0.26% 59
2022
Q3
$546K Buy
11,936
+2,363
+25% +$115K 0.22% 63
2022
Q2
$502K Buy
+9,573
New +$488K 0.2% 69

Other funds holding PFE

High Note Wealth's PFE Position: Q1 2026 in Review

High Note Wealth increased its Pfizer (PFE) stake by 4.9% in Q1 2026, buying an estimated $8.49K and bringing the position to 6,843 shares worth $192K. The position accounts for 0.04% of the portfolio, ranked #110.

High Note Wealth first reported a position in PFE in Q2 2022 and has held it in 16 quarters since. The position peaked at $617K in Q4 2022. 2,934 funds tracked by Wall St. Rank hold PFE as of Q1 2026.

  • High Note Wealth held 6,843 shares of Pfizer worth $192K as of Q1 2026.
  • High Note Wealth bought 319 Pfizer shares in Q1 2026, an estimated $8.49K.
  • Pfizer made up 0.04% of High Note Wealth's portfolio in Q1 2026, its #110 holding.
  • High Note Wealth first reported a position in Pfizer in Q2 2022 and has held it in 16 quarters since.
  • High Note Wealth's Pfizer position peaked at $617K in Q4 2022.
  • 2,934 funds tracked by Wall St. Rank held Pfizer as of Q1 2026.

Based on High Note Wealth's 13F filing for Q1 2026, filed 11 May 2026.